View in EDS HTML Full Text PDF Full Text

A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.

Saved in:
Bibliographic Details
Title: A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
Authors: Sun W; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA., Veeramachaneni N; Cardiothoracic Surgery Division, Department of Surgery, Saint Louis University School of Medicine, Saint Louis, Missouri, USA., Al-Rajabi R; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA., Madan R; Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas, USA., Kasi A; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA., Al-Kasspooles M; University of Kansas Cancer Center, Kansas City, Kansas, USA.; Division of Surgical Oncology, Department of Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA., Baranda J; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA., Saeed A; Hematology-Oncology Division, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., Phadnis MA; Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA., Godwin AK; University of Kansas Cancer Center, Kansas City, Kansas, USA.; Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas, USA., Olyaee M; Division of Gastroenterology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA., Streeter N; University of Kansas Cancer Center, Kansas City, Kansas, USA., Nagji A; University of Kansas Cancer Center, Kansas City, Kansas, USA.; Department of Cardiothoracic Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA., Dai J; Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas, USA., Williamson S; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA.
Source: Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (15), pp. 16098-16107. Date of Electronic Publication: 2023 Jun 16.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37326317
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sun+W%22">Sun W</searchLink>; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Veeramachaneni+N%22">Veeramachaneni N</searchLink>; Cardiothoracic Surgery Division, Department of Surgery, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.<br /><searchLink fieldCode="AU" term="%22Al-Rajabi+R%22">Al-Rajabi R</searchLink>; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Madan+R%22">Madan R</searchLink>; Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Kasi+A%22">Kasi A</searchLink>; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Al-Kasspooles+M%22">Al-Kasspooles M</searchLink>; University of Kansas Cancer Center, Kansas City, Kansas, USA.; Division of Surgical Oncology, Department of Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Baranda+J%22">Baranda J</searchLink>; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Saeed+A%22">Saeed A</searchLink>; Hematology-Oncology Division, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Phadnis+MA%22">Phadnis MA</searchLink>; Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Godwin+AK%22">Godwin AK</searchLink>; University of Kansas Cancer Center, Kansas City, Kansas, USA.; Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Olyaee+M%22">Olyaee M</searchLink>; Division of Gastroenterology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Streeter+N%22">Streeter N</searchLink>; University of Kansas Cancer Center, Kansas City, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Nagji+A%22">Nagji A</searchLink>; University of Kansas Cancer Center, Kansas City, Kansas, USA.; Department of Cardiothoracic Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Dai+J%22">Dai J</searchLink>; Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Williamson+S%22">Williamson S</searchLink>; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101595310%22">Cancer medicine</searchLink> [Cancer Med] 2023 Aug; Vol. 12 (15), pp. 16098-16107. <i>Date of Electronic Publication: </i>2023 Jun 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22John+Wiley+%26+Sons+Ltd%22">John Wiley & Sons Ltd </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101595310 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2045-7634 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220457634%22">20457634 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37326317
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cam4.6263
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 16098
    Titles:
      – TitleFull: A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sun W
      – PersonEntity:
          Name:
            NameFull: Veeramachaneni N
      – PersonEntity:
          Name:
            NameFull: Al-Rajabi R
      – PersonEntity:
          Name:
            NameFull: Madan R
      – PersonEntity:
          Name:
            NameFull: Kasi A
      – PersonEntity:
          Name:
            NameFull: Al-Kasspooles M
      – PersonEntity:
          Name:
            NameFull: Baranda J
      – PersonEntity:
          Name:
            NameFull: Saeed A
      – PersonEntity:
          Name:
            NameFull: Phadnis MA
      – PersonEntity:
          Name:
            NameFull: Godwin AK
      – PersonEntity:
          Name:
            NameFull: Olyaee M
      – PersonEntity:
          Name:
            NameFull: Streeter N
      – PersonEntity:
          Name:
            NameFull: Nagji A
      – PersonEntity:
          Name:
            NameFull: Dai J
      – PersonEntity:
          Name:
            NameFull: Williamson S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2023 Aug
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2045-7634
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 15
          Titles:
            – TitleFull: Cancer medicine
              Type: main
ResultId 1